|ID:946 ||Faecal Calprotectin||Search Links: General Info : Protocols : Patient Info|
|Description||Calprotectin is measured in a stool sample by ELISA. Calprotectin is excreted in excess into the intestinal lumen during inflammatory processes and can act as a marker for inflammatory diseases of the lower gastrointestinal tract. Intended to distinguish between inflammatory bowel disease and non-inflammatory bowel disease.|
|Indication|| Faecal calprotectin testing can support clinicians with the differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel sybdrome (IBS) in patients with recent onset lower gastrointestinal symptoms.|
|Additional Info|| This test should only be used according to the Leeds Map of Medicine Change In Bowel Habit (CIBH) pathway as a guide to differentiate between IBD and IBS (and other causes e.g. coeliac disease should be excluded separately). DO NOT USE if Cancer is suspected - follow the Leeds Map of Medicine CIBH pathway.|
|Interpretation||<50ug/g Low risk of IBD. For management as per primary care IBS guidelines.
>50ug/g Refer to Gastroenterology. This test should only be used according to the Leeds Map of Medicine CIBH pathway as a guide to differentiate between IBD and IBS (and other causes e.g. coeliac disease should be excluded separately)|
|Ref. Range (Male)||<50|
|Ref. Range (Female)|| <50|
|Ref. Range (Paed)|| |
|Ref. Range Notes|| |
|IP Acute TAT||14 days|
|IP Routine TAT||- Not Defined -|
|GP Acute TAT||14 days|
|GP Routine TAT||- Not Defined -|
|Turnround Comment||The assay is batch dependant|
Originally edited by : Anna McHugh. Last edited on 28/06/2017 10:03:31. Published By AM on 28/06/2016 10:03:31.